Mayne Pharma | MYX - Ebit

Stock Price
4.50
Daily Change
-0.78 -14.77%
Monthly
-10.00%
Yearly
-6.44%
Q3 Forecast
5.25

Mayne Pharma reported AUD-16200000 in EBIT for its fiscal semester ending in June of 2024.



Financials
Stock Price AUD
Assets AUD 1.14B
Cash and Equivalent AUD 110.07M
Cost of Sales AUD 43.74M
Current Assets AUD 460.59M
Current Liabilities AUD 313.94M
Debt AUD 38.82M
Dividend Yield 0
EBIT AUD -16.2M
EBITDA AUD -65.76M
Employees 900
EPS Earnings Per Share AUD -0.89
Equity Capital and Reserves AUD 454.19M
Gross Profit on Sales AUD 115.99M
Interest Expense on Debt AUD 1.2M
Loan Capital AUD 31.64M
Market Capitalization AUD 382.83M
Net Income AUD -103.68M
Operating Expenses AUD 103.54M
Operating Profit AUD -3.3M
Ordinary Share Capital AUD 1.22B
Pre-Tax Profit AUD -57.61M
Sales Revenues AUD 195.04M
Selling and Administration Expenses AUD 54.8M
Stock AUD 74.63M
Trade Creditors AUD 20.87M
Trade Debtors AUD 193.22M

Ebit Change Date
Ansell USD 117.3M 39.1M Jun/2024
Avita Medical AUD -10272000 22.56M Dec/2024
Cochlear AUD 275M 25.5M Dec/2024
CSL USD 2.75B 1.35B Dec/2024
Healius AUD 23.7M 26M Dec/2024
Integral Diagnostics AUD 24.99M 5.08M Jun/2024
Medical Developments International AUD -12124000 3.97M Jun/2023
Nanosonics AUD 8.7M 2.6M Dec/2024
Next Science USD -8249260 2.13M Jun/2023
Polynovo AUD 840K 147K Jun/2024
Ramsay Health Care AUD 500.1M 14.8M Dec/2024
ResMed USD 456.57M 20.65M Jun/2025
Sigma Healthcare AUD 6.86M 2.15M Jul/2024
Sonic Healthcare AUD 423.94M 80.3M Dec/2024
Telix Pharmaceuticals AUD 37.44M 16.38M Dec/2024